Overview

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Status:
Recruiting

Trial end date:
2029-07-15

Target enrollment:

Participant gender:

Summary

In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone acetate
Lenalidomide